Grail Shares Rise Amid Earnings Report and Upcoming ASCO Presentation
Grail shares increased by 14% this week following its first-quarter earnings report and positive commentary ahead of a presentation at the American Society of Clinical Oncology (ASCO) meeting. Despite recent gains, Grail's stock is still down nearly 28% year-to-date due to disappointing results from a large-scale trial with England’s NHS.
Tickers: $GRAL
Topics: ASCO meeting clinical trial results FDA approval Galleri test Grail